Loading organizations...

§ Private Profile · 595 Madison Ave, New York, NY 10022, USA
AI document authoring platform for regulatory professionals in life…
Vespper has raised $500K across 1 funding round.
Key people at Vespper.
Vespper was founded in 2024 by Dudu Lasry (Founder) and Topaz Turkenitz (Founder).
Vespper has raised $500K in total across 1 funding round.
Vespper is an AI document authoring platform for regulatory professionals in pharma, med-tech and biotech companies.
Vespper was founded in 2024 by Dudu Lasry (Founder) and Topaz Turkenitz (Founder).
Vespper has raised $500K in total across 1 funding round.
Vespper's investors include Y Combinator, ZAKA Ventures.
Vespper is an AI-powered document authoring platform designed specifically for regulatory professionals in pharmaceutical, med-tech, and biotech companies. It leverages domain-specific AI to assist users in drafting regulatory documents, researching regulations, and automating life-science workflows, thereby improving efficiency and accuracy in compliance-heavy environments[4][6]. The platform integrates with internal tools to triage alerts, troubleshoot issues, and surface relevant data quickly, helping regulatory teams manage complex documentation and regulatory demands more effectively[4].
Vespper was founded by active engineers who experienced firsthand the challenges of managing overwhelming alerts and regulatory documentation in life sciences. The idea emerged from the need to democratize expert knowledge and reduce the monotony of manual triaging and document drafting, enabling professionals to focus on higher-impact work[4]. While specific founding year and founder names are not detailed in the available information, the company’s evolution centers on combining AI with classic AIOps and heuristic methods derived from practical experience to create a multi-agent system tailored for regulatory workflows[4].
Vespper rides the growing trend of AI-driven automation in life sciences regulatory affairs, a sector increasingly burdened by complex compliance requirements and voluminous documentation. The timing is critical as pharmaceutical and biotech companies seek to accelerate drug development and regulatory submissions while maintaining high standards of accuracy and compliance. Market forces such as digital transformation, AI adoption in regulated industries, and the need for scalable, integrated solutions favor platforms like Vespper. By democratizing expert knowledge and automating routine tasks, Vespper influences the broader ecosystem by enabling regulatory teams to be more productive and responsive[4][6].
Looking ahead, Vespper is poised to expand its AI capabilities and integrations, potentially incorporating more advanced generative AI models and broader regulatory content coverage. Trends such as increased regulatory complexity, demand for faster drug approvals, and AI adoption in life sciences will shape its growth trajectory. Vespper’s influence may evolve from a niche regulatory tool to a comprehensive AI assistant embedded deeply within life sciences organizations’ compliance and R&D workflows, driving both operational efficiency and innovation.
In summary, Vespper exemplifies the convergence of AI and regulatory expertise, addressing a critical pain point in life sciences with a sophisticated, user-friendly platform that promises to transform how regulatory professionals author and manage documents.
Key people at Vespper.
Vespper has raised $500K across 1 funding round. Most recently, it raised $500K Seed in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $500K Seed | — | Y Combinator, Zaka Ventures | Announced |